Algul Durak Beyza, Karakan Mine Sebnem
Nephrology, Ankara City Hospital, Ankara, TUR.
Nephrology, Ankara Yildirim Beyazit University, Ankara, TUR.
Cureus. 2020 Feb 29;12(2):e7140. doi: 10.7759/cureus.7140.
Purpose The aim of this study was to evaluate the relationship between Fibroblast Growth Factor-23 (FGF23) serum levels and cardiovascular disease and early graft failure in renal transplant recipients. Methods This cross-sectional study was conducted on renal transplant recipients followed by our adult kidney transplant clinic. The patients were divided into two groups according to the mean FGF23 levels (mean FGF23 level=71.2 ± 34.6pg/mL). The patients included in the study were classified as Group 1 (FGF23 <71 pg/mL, n= 42) and Group 2 (FGF23 ≥ 71pg/mL, n= 46) and the data was analyzed as a statistical significance between the two groups. The presence of atherosclerosis was determined by a Doppler ultrasound for evaluate the carotid artery intima-media thickness (CA-IMT). Intrarenal Doppler spectra were obtained with same Doppler ultrasound to determine the renal resistivity index (RRI) for evaluate graft renal failure. Results A total of 88 kidney transplantation recipients were included in the study. In the multivariate analysis adjusted for age and gender, the eGFR (β =-0.217, p=0.048), CA-IMT (β =0.318, p=0.009) and RRI (β =0.246, p=0.019) parameters were statistically significant, while the remaining parameters were not statistically significant. In the group analysis, Ca (9.6 ± 0.3 vs. 8.8 ± 0,2, p< 0.05), CA-IMT (0.9 ± 0.2, vs. 0.6 ± 0.3, p< 0.05) and RRI (0.69 ± 0.04 vs. 0.60 ± 0.01, p< 0.05) were significantly higher in the patients in group 2 than the patients in group 1. Conclusion According to our results, FGF23 can be considered as a descriptive biomarker for cardiovascular prognosis and graft function for patients with kidney transplantation.
目的 本研究旨在评估肾移植受者血清成纤维细胞生长因子23（FGF23）水平与心血管疾病及早期移植肾失功之间的关系。方法 本横断面研究在我院成人肾移植门诊随访的肾移植受者中进行。根据FGF23平均水平（平均FGF23水平 = 71.2 ± 34.6pg/mL）将患者分为两组。纳入研究的患者分为第1组（FGF23 <71 pg/mL，n = 42）和第2组（FGF23≥71pg/mL，n = 46），并对两组间的数据进行统计学显著性分析。通过多普勒超声评估颈动脉内膜中层厚度（CA - IMT）以确定动脉粥样硬化的存在。使用同一台多普勒超声获取肾内多普勒频谱，以确定肾阻力指数（RRI）来评估移植肾失功。结果 本研究共纳入88例肾移植受者。在对年龄和性别进行校正的多因素分析中，估算肾小球滤过率（eGFR，β = -0.217，p = 0.048）、CA - IMT（β = 0.318，p = 0.009）和RRI（β = 0.246，p = 0.019）参数具有统计学显著性，而其余参数无统计学显著性。在组间分析中，第2组患者的血钙（9.6 ± 0.3 vs. 8.8 ± 0.2，p < 0.05）、CA - IMT（0.9 ± 0.2 vs. 0.6 ± 0.3，p < 0.05）和RRI（0.69 ± 0.04 vs. 0.60 ± 0.01，p < 0.05）显著高于第1组患者。结论 根据我们的研究结果，FGF23可被视为肾移植患者心血管预后和移植肾功能的描述性生物标志物。
